Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nephros (NEPH) Share-based Compensation (2016 - 2025)

Historic Share-based Compensation for Nephros (NEPH) over the last 17 years, with Q3 2025 value amounting to $70000.0.

  • Nephros' Share-based Compensation rose 769.23% to $70000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $279000.0, marking a year-over-year decrease of 4199.58%. This contributed to the annual value of $153000.0 for FY2024, which is 8545.63% down from last year.
  • As of Q3 2025, Nephros' Share-based Compensation stood at $70000.0, which was up 769.23% from $71000.0 recorded in Q2 2025.
  • Nephros' 5-year Share-based Compensation high stood at $434000.0 for Q4 2021, and its period low was -$9000.0 during Q1 2024.
  • Its 5-year average for Share-based Compensation is $192789.5, with a median of $194000.0 in 2023.
  • In the last 5 years, Nephros' Share-based Compensation crashed by 10282.13% in 2024 and then soared by 94444.44% in 2025.
  • Over the past 5 years, Nephros' Share-based Compensation (Quarter) stood at $434000.0 in 2021, then tumbled by 58.76% to $179000.0 in 2022, then skyrocketed by 117.88% to $390000.0 in 2023, then crashed by 84.1% to $62000.0 in 2024, then increased by 12.9% to $70000.0 in 2025.
  • Its Share-based Compensation stands at $70000.0 for Q3 2025, versus $71000.0 for Q2 2025 and $76000.0 for Q1 2025.